Bring advanced cardiac imaging to your practice with a mobile PET/CT solution designed to improve diagnostic confidence, reduce radiation exposure, and support a better patient experience. Modern Nuclear helps clinics expand cardiac imaging capabilities without the burden of permanent on-site installation.
Modern Nuclear’s mobile cardiac PET/CT service helps physicians access higher-quality myocardial perfusion imaging with the convenience of on-site delivery. With support for Flurpiridaz F 18 imaging, your team can offer a modern PET-based diagnostic pathway designed to improve image quality, strengthen interpretation, and support better patient care.
Flurpiridaz F 18 injection was approved by the FDA in 2024 for PET myocardial perfusion imaging in adults with known or suspected coronary artery disease, and GE HealthCare says it provides higher diagnostic efficacy than SPECT MPI.
Flyrcado, GE HealthCare’s flurpiridaz F 18 injection, offers a new PET myocardial perfusion imaging option for adults with known or suspected coronary artery disease. GE HealthCare states that it delivers higher diagnostic efficacy than SPECT MPI and may help expand access to PET imaging due to its practical distribution model and longer half-life compared with currently approved cardiac PET radiotracers.
Great imaging is not only about data. It is also about the experience. Modern Nuclear’s mobile imaging trailers are designed to create a calm, comfortable environment that supports a smoother visit for patients while helping partner clinics deliver advanced imaging with minimal disruption.
Modern Nuclear has helped healthcare providers expand access to advanced imaging for decades. Our mobile cardiac PET/CT program combines proven operational experience, dependable service, and technology designed to improve diagnostic quality and patient care.